BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

239 related articles for article (PubMed ID: 23056398)

  • 1. Direct assessment of the effect of the Gly380Arg achondroplasia mutation on FGFR3 dimerization using quantitative imaging FRET.
    Placone J; Hristova K
    PLoS One; 2012; 7(10):e46678. PubMed ID: 23056398
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of the achondroplasia mutation on FGFR3 dimerization and FGFR3 structural response to fgf1 and fgf2: A quantitative FRET study in osmotically derived plasma membrane vesicles.
    Sarabipour S; Hristova K
    Biochim Biophys Acta; 2016 Jul; 1858(7 Pt A):1436-42. PubMed ID: 27040652
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Physical basis behind achondroplasia, the most common form of human dwarfism.
    He L; Horton W; Hristova K
    J Biol Chem; 2010 Sep; 285(39):30103-14. PubMed ID: 20624921
    [TBL] [Abstract][Full Text] [Related]  

  • 4. FGFR3 heterodimerization in achondroplasia, the most common form of human dwarfism.
    He L; Shobnam N; Wimley WC; Hristova K
    J Biol Chem; 2011 Apr; 286(15):13272-81. PubMed ID: 21324899
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Characterization of membrane protein interactions in plasma membrane derived vesicles with quantitative imaging Förster resonance energy transfer.
    Sarabipour S; Del Piccolo N; Hristova K
    Acc Chem Res; 2015 Aug; 48(8):2262-9. PubMed ID: 26244699
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of the G375C and G346E achondroplasia mutations on FGFR3 activation.
    He L; Serrano C; Niphadkar N; Shobnam N; Hristova K
    PLoS One; 2012; 7(4):e34808. PubMed ID: 22529939
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Studies of receptor tyrosine kinase transmembrane domain interactions: the EmEx-FRET method.
    Merzlyakov M; Chen L; Hristova K
    J Membr Biol; 2007 Feb; 215(2-3):93-103. PubMed ID: 17565424
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The achondroplasia mutation does not alter the dimerization energetics of the fibroblast growth factor receptor 3 transmembrane domain.
    You M; Li E; Hristova K
    Biochemistry; 2006 May; 45(17):5551-6. PubMed ID: 16634636
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Typical achondroplasia secondary to a unique insertional variant of FGFR3 with in vitro demonstration of its effect on FGFR3 function.
    Meyer AN; Modaff P; Wang CG; Wohler E; Sobreira NL; Donoghue DJ; Pauli RM
    Am J Med Genet A; 2021 Mar; 185(3):798-805. PubMed ID: 33368972
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Suppression of severe achondroplasia with developmental delay and acanthosis nigricans by the p.Thr651Pro mutation.
    Manickam K; Donoghue DJ; Meyer AN; Snyder PJ; Prior TW
    Am J Med Genet A; 2014 Jan; 164A(1):243-50. PubMed ID: 24352917
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mutant FGFR3 associated with SADDAN disease causes cytoskeleton disorganization through PLCγ1/Src-mediated paxillin hyperphosphorylation.
    Montone R; Romanelli MG; Baruzzi A; Ferrarini F; Liboi E; Lievens PM
    Int J Biochem Cell Biol; 2018 Feb; 95():17-26. PubMed ID: 29242050
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Knock-in human FGFR3 achondroplasia mutation as a mouse model for human skeletal dysplasia.
    Lee YC; Song IW; Pai YJ; Chen SD; Chen YT
    Sci Rep; 2017 Feb; 7():43220. PubMed ID: 28230213
    [TBL] [Abstract][Full Text] [Related]  

  • 13. p.Ser348Cys mutation in FGFR3 gene leads to "Mild ACH /Severe HCH" phenotype.
    Bengur FB; Ekmekci CG; Karaarslan E; Gunoz H; Alanay Y
    Eur J Med Genet; 2020 Feb; 63(2):103659. PubMed ID: 31048079
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification and in silico characterization of p.G380R substitution in FGFR3, associated with achondroplasia in a non-consanguineous Pakistani family.
    Ajmal M; Mir A; Shoaib M; Malik SA; Nasir M
    Diagn Pathol; 2017 Jul; 12(1):47. PubMed ID: 28679403
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reduced binding of FGF1 to mutant fibroblast growth factor receptor 3.
    Khnykin D; Olsnes S
    Growth Factors; 2006 Jun; 24(2):111-9. PubMed ID: 16801131
    [TBL] [Abstract][Full Text] [Related]  

  • 16. FGFR3 targeting strategies for achondroplasia.
    Laederich MB; Horton WA
    Expert Rev Mol Med; 2012 Jan; 14():e11. PubMed ID: 22559284
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Novel phenotype of achondroplasia due to biallelic FGFR3 pathogenic variants.
    Chang IJ; Sun A; Bouchard ML; Kamps SE; Hale S; Done S; Goldberg MJ; Glass IA
    Am J Med Genet A; 2018 Jul; 176(7):1675-1679. PubMed ID: 30160829
    [TBL] [Abstract][Full Text] [Related]  

  • 18. FGFR3 mutation causes abnormal membranous ossification in achondroplasia.
    Di Rocco F; Biosse Duplan M; Heuzé Y; Kaci N; Komla-Ebri D; Munnich A; Mugniery E; Benoist-Lasselin C; Legeai-Mallet L
    Hum Mol Genet; 2014 Jun; 23(11):2914-25. PubMed ID: 24419316
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Novel FGFR3 mutations creating cysteine residues in the extracellular domain of the receptor cause achondroplasia or severe forms of hypochondroplasia.
    Heuertz S; Le Merrer M; Zabel B; Wright M; Legeai-Mallet L; Cormier-Daire V; Gibbs L; Bonaventure J
    Eur J Hum Genet; 2006 Dec; 14(12):1240-7. PubMed ID: 16912704
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A New Method to Study Heterodimerization of Membrane Proteins and Its Application to Fibroblast Growth Factor Receptors.
    Del Piccolo N; Sarabipour S; Hristova K
    J Biol Chem; 2017 Jan; 292(4):1288-1301. PubMed ID: 27927983
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.